Innovating Works

BIOMERIEUX SA

Desconocido
MALDIBANK: Multi domain Open MALDI Spectra Archive for Identification of Microorganisms MALDIBANK: A Comprehensive Solution to Microbial Challenges In an era marked by pressing environmental and health challenges, including cli...
2024-10-23 - 2029-04-30 | Financiado
SYNSENSO: Cell-free synthetic biology for combinatorial biosensor design BIOMERIEUX SA participó en un HORIZON EUROPE: HORIZON-MSCA-2021-DN-01 Recent advances in the field of synthetic biology offer an unprecedented opportunity for next-generation biosensors characterized by program...
2022-07-13 - 2026-08-31 | Financiado
UNDINE: The human genetic and immunological determinants of the clinical manifestations of SARS-CoV-2 infect... BIOMERIEUX SA participó en un HORIZON EUROPE: HORIZON-HLTH-2021-DISEASE-04 "The consequences of SARS-CoV-2 exposure range from a lack of infection to lethal COVID-19. This immense inter-individual clinical variabili...
2022-05-20 - 2026-05-31 | Financiado
TTV GUIDE TX: PERSONALISATION OF IMMUNOSUPPRESSION BY MONITORING VIRAL LOAD POST KIDNEY TRANSPLANTATION A RANDOM... BIOMERIEUX SA participó en un H2020: H2020-SC1-BHC-2018-2020 Challenge: End stage renal disease (ESRD) causes high socioeconomic burden for citizens and the healthcare system in Europe. Kidney transpla...
2021-02-02 - 2026-04-30 | Financiado
DIAMONDS: Diagnosis and Management of Febrile Illness using RNA Personalised Molecular Signature Diagnosis BIOMERIEUX SA participó en un H2020: H2020-SC1-BHC-2018-2020 Our proposal will address the challenge of bringing personalised medicine into routine use in EU healthcare systems for diagnosis and treatm...
2019-12-06 - 2025-06-30 | Financiado
ImmunoSep: Personalized immunotherapy in sepsis a precision medicine based approach BIOMERIEUX SA participó en un H2020: H2020-SC1-BHC-2018-2020 Sepsis is a life-threatening organ dysfunction caused by a dysregulated host response to infection, and is characterized by a high mortality...
2019-12-05 - 2024-06-30 | Financiado
VALUE-Dx: The value of diagnostics to combat antimicrobial resistance by optimising antibiotic use Antimicrobial resistance (AMR) is of great public health concern, causing numerous losses of lives worldwide and threatening to reverse many...
2019-03-25 - 2024-09-30 | Financiado
VITAL: Vaccines and Infectious Diseases in the Ageing PopuLation BIOMERIEUX SA participó en un H2020: H2020-JTI-IMI2-2017-12-two-stage Today’s major challenge is to improve efficacy of vaccines to protect the growing ageing population against infectious diseases (ID). The VI...
2018-12-10 - 2024-12-31 | Financiado
COMBACTE-CDI: Combatting Bacterial Resistance in Europe Clostridium Difficile Infections BIOMERIEUX SA participó en un H2020: H2020-JTI-IMI2-2016-09-two-stage Clostridium difficile infection (CDI) is one of the most prevalent healthcare associated infections, affecting both hospitalized patients an...
2017-10-27 - 2021-04-30 | Financiado
ViBrANT: VIral and BacteRial Adhesin Network Training BIOMERIEUX SA participó en un H2020: H2020-MSCA-ITN-2017 ViBrANT (VIral and BacteRial Adhesin Network Training) brings together an interdisciplinary team of world-leading European infection researc...
2017-08-31 - 2022-06-30 | Financiado
ESA -ITN: European Sepsis Academy towards new biomarkers to improve sepsis management BIOMERIEUX SA participó en un H2020: H2020-MSCA-ITN-2015 ESA-ITN will break through the state of the art in sepsis diagnostics and will train 15 early-stage researchers (ESRs) to determine the clin...
2016-02-11 - 2020-02-29 | Financiado
PERFORM: Personalised Risk assessment in febrile illness to Optimise Real life Management across the European... BIOMERIEUX SA participó en un H2020: H2020-PHC-2014-2015 The management of febrile patients is one of the most common and important problems facing healthcare providers. Distinction between bacteri...
2015-12-01 - 2021-06-30 | Financiado
ND4ID: New Diagnostics for Infectious Diseases ND4ID Infectious diseases are a major burden to public health and the global economy, not in the least due to antimicrobial resistance. Rapid poin...
2015-07-31 - 2020-02-29 | Financiado
CLOSPORE: UNDERSTANDING THE CLOSTRIDIUM SPORE A PREREQUISTE FOR DISEASE INTERVENTIONS AND EXPLOITATION BIOMERIEUX SA participó en un H2020: H2020-MSCA-ITN-2014 Bacterial endospores are the most resistant life-forms on earth and the most important single feature of the genus Clostridium. Thus, whilst...
2014-12-16 - 2018-12-31 | Financiado
PREPARE: Platform foR European Preparedness Against Re emerging Epidemics BIOMERIEUX SA participó en un FP7: Far from receding, the threats posed by infections with epidemic potential grow ever greater. Although Europe has amongst the best healthcar...
Financiado
* Datos extraídos de la documentos o webs disponibles en diferentes organismos públicos.